ST红太阳(000525) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥860,778,536.56, representing a 16.97% increase compared to ¥735,873,844.81 in the same period last year[8] - Net profit attributable to shareholders was ¥22,097,914.19, a significant increase of 187.17% from ¥7,695,081.96 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥6,082,305.44, recovering from a loss of ¥47,060,511.32 in the previous year, marking a 112.92% improvement[8] - Basic earnings per share increased to ¥0.0381, a rise of 186.47% compared to ¥0.0133 in the previous year[8] - Operating profit increased by 247.41% to RMB 31,110,888.59 from RMB 8,955,121.33[17] - Net profit grew by 242.91%, reaching RMB 19,623,496.09 compared to RMB 5,722,705.17[17] - Total profit rose by 265.64% to RMB 33,274,660.74 from RMB 9,100,340.38[17] - Total operating revenue for Q1 2021 was CNY 860,778,536.56, an increase of 16.9% compared to CNY 735,873,844.81 in Q1 2020[46] - The total operating profit for the first quarter was CNY 31,110,888.59, compared to CNY 8,955,121.33 in the previous year, representing a significant increase[48] Cash Flow - The net cash flow from operating activities was ¥63,905,357.47, up 103.83% from ¥31,353,049.02 in the same period last year[8] - The company reported a significant increase in cash received from product sales during the reporting period[17] - The cash inflow from operating activities totaled ¥332,667,956.90, an increase from ¥249,020,937.81 in the previous year[59] - The company experienced a net cash outflow from operating activities of ¥34,389,730.54, worsening from a net outflow of ¥7,105,659.34 in the previous year[59] - Total cash outflow from operating activities amounted to ¥1,101,501,524.93, up from ¥964,271,602.24, indicating a 14.2% increase[56] - The company reported a net cash outflow from investment activities of ¥25,636,157.12, an improvement from a net outflow of ¥81,440,415.80 in the previous year[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥11,520,565,373.97, a slight decrease of 0.19% from ¥11,542,748,161.82 at the end of the previous year[8] - Net assets attributable to shareholders increased to ¥4,034,732,381.06, reflecting a 0.64% growth from ¥4,008,906,990.44 at the end of the previous year[8] - The total liabilities decreased slightly to approximately ¥5.65 billion from ¥5.59 billion, showing a stable financial position[37] - The proportion of non-operating funds occupied by major shareholders reached 73.95% of the latest audited net assets, highlighting liquidity concerns[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,447[12] - The largest shareholder, Nanjing First Pesticide Group Co., Ltd., held 44.77% of the shares, totaling 260,018,331 shares[12] Government and Regulatory Matters - The company received government subsidies amounting to ¥14,577,774.98 during the reporting period[9] - The company is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws[21] Operational Insights - The increase in revenue is primarily attributed to the rise in product prices and sales volume, leading to increased profitability[12] - The company has committed to a performance compensation agreement with Jiangsu Hongtai Pharmaceutical Group, ensuring a total audited net profit of no less than 36,898.12 million yuan for the years 2018 to 2021[24] - The company has seen a reduction in fixed asset purchases during the reporting period, which has positively impacted cash flow[18] - The company has reduced financing borrowings during the reporting period, contributing to improved financial stability[19] Compliance and Internal Control - The company plans to enhance compliance awareness and improve internal control systems to prevent similar issues in the future[32] - The company has not engaged in any investor relations activities during the reporting period, indicating a focus on internal management[33] Research and Development - Research and development expenses for Q1 2021 were CNY 21,304,234.40, down from CNY 29,534,992.07 in Q1 2020, indicating a decrease of 27.8%[47]